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INTRODUCTION
Glutaric aciduria or acidemia type I (OMIM # 231670, GA
I) is an inborn error of metabolism caused by a deficiency of
glutaryl-CoA dehydrogenase (GCDH) encoded by the GCDH
gene. GCDH catalyzes the conversion of glutaryl-CoA (GA)
to crotonyl-CoA in the metabolic pathway for lysine, hydrox-
ylysine, and tryptophan (1). An accumulation of GA and 3-
OH-GA is established as the biochemical hallmark of GA I,
resulting in acute basal ganglia injury, movement disorders,
and further neuropsychologic deterioration (2). Since the first
description of the two index cases in 1975 (3), over 400 pat-
ients and 150 disease causing mutations have been reported
(4). The estimated worldwide frequency of GA I is one in
100,000 newborns (5). However, this estimate was based on
the tandem mass spectrometry newborn screening results con-
ducted in several countries including the USA, Australia, and
Germany. Since GA I is not included in the routine newborn
screening program in Korea, exact frequency of this disorder
could not be estimated. Only two cases had been reported in
the Korean literature diagnosed on the basis of clinical features
and results of urine organic acid analysis. Here, we report two
Korean patients with GA I, proven by mutational analysis,
which revealed two novel mutations, for the first time in Korea.
CASE REPORT
Patient 1
A 10-month-old female infant was referred to our hospital
for developmental delay and large head size. She was born to
unrelated healthy parents after a 41-week pregnancy. Alth-
ough she could smile responsively and feed well, complete
head control had not been achieved. She had never suffered
from metabolic decompensation episodes, such as mental det-
erioration or seizures associated with infection or fever. Brain
magnetic resonance imaging (MRI) revealed large amounts
of bilateral subdural fluid collection, cerebral atrophy, and
high signal intensity in both basal ganglia (Fig. 1A). After
surgical drainage of subdural fluids, recurrent subdural bleed-
ing, systemic infection, decreased mentality, and seizures occ-
urred. These symptoms were not easily controlled in the ensu-
ing postoperative period. Under the suspicion of metabolic
encephalopathies, urine organic acid analysis was conducted,
which revealed high levels of GA (7,360.9 mM/M Cr, ref:
<5.3) and 3-OH-GA (67.6 mM/M Cr ref: <4.2). We ana-
lyzed the GCDH gene and identified compound heterozygote
mutations of p.Ser139Leu and p.Asp220Tyr (Fig. 1B). Her
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Glutaric Aciduria Type 1 in Korea: Report of Two Novel Mutations
Glutaric aciduria type I (GA I) is an autosomal recessive disorder caused by a defi-
ciency of glutaryl-CoA dehydrogenase. Although over 400 patients confirmed as GA
I have been reported, reports from the Asian population had contributed to the minor
proportion. We recently diagnosed two cases of GA I confirmed with mutational anal-
ysis. Here, we present their rather atypical clinical presentations with genetic char-
acteristics for the first time in Korea. Profound developmental delay from birth, asso-
ciation of hearing loss, and neurological improvement after surgical intervention, were
considered to be different clinical features from most reported cases. One patient
was a compound heterozygote for p.Ser139Leu and p.Asp220Tyr, and the other
for p.Ser139Leu and Glu160X. The mutations of the two alleles (p.Asp220Tyr and
p.Glu160X) were novel and reports of p.Ser139Leu were rare both in Western and
other Asian populations. These might suggest different genetic spectrum of Korean
GA I patients.
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and father was a heterozygote carrier for p.Asp220Tyr. Elder
brother who was phenotypically normal did not harbor any
of the two mutations.
After specific treatment for GA I, including a special pro-
tein restriction formula (Glutarex-1, Abbott) with supple-
mentation of L-carnitine (100 mg/kg/day) and riboflavin (100
mg/day), the patient recovered from postoperative complica-
tions and her general condition improved. However, her swal-
lowing remained impaired, requiring tube feeding, and her
development remained delayed.
Patient 2
A 3-yr-old male, born from unrelated healthy parents after
a 39-week pregnancy, was referred to our hospital for devel-
opmental delay. Large head size and hearing impairment were
detected in the neonatal care unit soon after birth. His motor
development was not delayed until six months of age when
he could support weight on his forearms and roll over. Sub-
sequently, he lost his motor skills gradually over 1 month
without any intervening episodes such as infection or seizures.
A brain MRI revealed asymmetric subdural fluid collection,
suggesting hemorrhage with a mild mass effect (Fig. 1C).
After surgical drainage, his motor skills improved to be able
to creep at the age of 13 months. Metabolic screening tests,
performed before a cochlear implantation procedure conduct-
ed at the age of 29 months, detected highly elevated GA
(73.75 mM/M Cr, ref: <5.3) and 3-OH-GA (12.1 mM/M
Cr, ref: <4.2) levels from urine organic acid analysis. We ana-
lyzed the GCDH gene and found compound heterozygote
mutations of p.Glu160X (Fig. 1D) and p.Ser139Leu. The
patient was treated with a special formula (Glutarex-1, Ab-
bott), L-carnitine (100 mg/kg/day) and riboflavin (100 mg/
day). He can now walk with assistance and did not show any
features of movement disorder until his current age of three
years.
Genetic analysis
Genomic DNA was extracted from peripheral blood leu-
Fig. 1. Magnetic resonance imaging (MRI) findings and GCDH gene mutational analysis of two patients. (A) MRI of the patient 1. A T2-weight-
ed axial image showing a large amount of subdural fluid collection with frontotemporal atrophy and high signal intensity in both basal gan-
glia. (B) A novel mutation from the patient 1. c.658G>T, heterozygote, p.Asp220Tyr. (C) MRI of the patient 2. Asymmetric subdural fluid
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kocytes using a Puregene DNA isolation kit (Gentra Systems,
Inc., Minneapolis, MN, USA). PCR was performed to amp-
lify the entire coding and flanking regions of all exons of the
GCDH gene. The primers were designed using Primer 3
(http://frodo.wi.mit.edu/) and the Refseq of GCDH (NC_
000019.8, NM_000159.2). Amplified products were sequ-
enced bidirectionally on an ABI PRISM 3100 Genetic Ana-
lyzer (Applied Biosystems, Foster City, CA, USA), then ana-
lyzed using the Seqscape v2.5 software. To determine the sig-
nificance of novel missense variations, we screened the allele
frequency in 100 normal subjects and analyzed interspecies
amino acid conservation using ClustalW. The mutation nom-
enclature followed the recommendations of the Human Gen-
ome Variation Society. Informed consent was obtained from
the parents of each patient for genetic study of blood samples.
Urine organic acid was measured by gas chromatography and
a mass selective detector.
DISCUSSION
Although the pathogenic mechanism of specific central ner-
vous system injury has not been established well, clinical and
laboratory features have been well characterized recently from
international cross-sectional study in 35 metabolic centers
(2). Most of the symptomatic patients (185/218, 85%), had
an acute encephalopathic crisis defined by acute neurologi-
cal deterioration associated with infection or seizure. The
study also pointed out that only limited patients developed
neurologic deterioration without a reported crisis. Compared
to these typical clinical courses, we found several different
clinical features in our patients. Patient 1 had already showed
delayed development and abnormal signals in both basal
ganglia on MRI before acute encephalopathic crisis, suggest-
ing that there was a preexisting injury before acute encephalo-
pathic crisis. Patient 2 did not seem to have an overt acute
encephalopathic crisis during the disease course. Sensory neu-
ral hearing loss, which was not reported to be an associated
findings with GA I, was present before we diagnosed GA I.
We performed surgical procedures in both patients before a
diagnosis of GA I. We supposed chronic subdural hematoma
or fluid collection partly contributed to delayed development
in both patients. Interestingly, patient 2 showed much im-
provement in development after the surgical procedure, while
patient 1 experienced no benefit but more deterioration. Asy-
mmetric subdural fluid collection in patient 2 might be res-
ponsible for sub-acute neurological deterioration, consider-
ing the fact that patient 2 showed near normal neurodevel-
opment before deterioration. Recently published manage-
ment guidelines of GA I recommended that neurosurgical
intervention for subdural hemorrhage should be decided cau-
tiously and conducted in limited, acute, life threatening cir-
cumstances including considerable mass effect or increased
pressure (4). However, surgical intervention could play some
beneficial role in carefully selected patients in addition to life
threatening conditions, if acute or subacute deterioration of
neurological status is suspected to be associated with subdu-
ral hematoma or fluid collection from clinical ground.
Our patients had compound heterozygote mutations in the
GCDH. Patient 1 had a G-to-T transition (c.658G>T) in exon
8 (p.Asp220Tyr) and the other allele mutation was a C-to-T
transition (c.416C>T) in exon 6 (p.Ser139Leu), which was
also found in patient 2. A C-to-T transition (c.478C>T) in
exon 6 (p.Glu160X) was the other mutation found in the pat-
ient 2. Among these, p.Glu160X and p.Asp220Tyr are novel
mutations. They are thought to be disease-causing mutations
because one is a nonsense mutation and the amino acid change
caused by the other mutation is highly conservative, and we
could not find this missense mutation in 200 alleles of normal
controls. The most frequently found mutation in the Euro-
pean population is known to be p.Arg402Trp ranging from
16% to 40% (6). In Hong Kong and Tawian Chinese, IVS
10-2AC is the recurrent mutation (7, 8). Three point muta-
tions including two novel mutations (p.Ser305Leu, p.Met-
339Val, p.Arg355His) were reported in two Japanese patients
(9). Although, the common mutation of our patients, p.Ser-
139Leu, was first reported in 1998 from Western population
(10), few reports have discussed the biochemical or clinical
phenotype of this mutation after that. To date, two Korean
GA I patients have been reported, diagnosed by urine organic
acid analysis and typical brain MRI findings in Korean litera-
ture (11, 12).
In conclusion, we have described two patients with GA I,
who displayed minor clinical differences to previous reports,
proven by mutational analysis of the GCDH, for the first time
in Korea. More GA I patients are expected to be diagnosed
before acute encephalopathic crisis with more widespread use
of MRI and newborn screening by tandem mass spectrome-
try. In these circumstances, mutation analysis will have a par-
ticularly important role for confirming the diagnosis of GA
I. We hope, from the present study, more GA I patients would
be diagnosed in the early course of disease and the genetic and
clinical characteristics of GA I in the Korean population would
be further clarified.
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